share_log

Maxim Group Upgrades NLS Pharmaceutics to Buy, Announces $4 Price Target

Maxim Group Upgrades NLS Pharmaceutics to Buy, Announces $4 Price Target

Maxim Group 将 NLS Pharmics 升级为买入,宣布目标股价为 4 美元
Benzinga Real-time News ·  2022/12/08 08:42

Maxim Group analyst Jason McCarthy upgrades NLS Pharmaceutics (NASDAQ:NLSP) from Hold to Buy and announces $4 price target.

Maxim Group分析师Jason McCarthy将NLS制药(纳斯达克:NLSP)从持有上调至买入,并宣布目标价4美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发